Creasallis

4 known investors

Creasallis develops CreaTap, a patented "plug-and-play" antibody modification technology that improves the penetration of antibody-based drugs into solid tumours, applicable to monoclonal, bispecific, and antibody-drug conjugates. It serves biopharmaceutical companies developing oncology therapeutics and is also building its own suite of antibody therapeutics with enhanced tumour penetration.